{"id":33690,"date":"2025-05-19T17:52:58","date_gmt":"2025-05-19T09:52:58","guid":{"rendered":"https:\/\/flcube.com\/?p=33690"},"modified":"2025-05-19T17:52:59","modified_gmt":"2025-05-19T09:52:59","slug":"sino-biopharmaceuticals-qp001-meloxicam-approved-by-nmpa-and-fda-for-postoperative-pain","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33690","title":{"rendered":"Sino Biopharmaceutical&#8217;s QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain"},"content":{"rendered":"\n<p>China-based Sino Biopharmaceutical Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>) announced that its Category 2.2 drug QP001 (meloxicam) has received marketing approvals from China\u2019s National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA). This milestone marks QP001 as the first daily 24-hour long-acting nonsteroidal anti-inflammatory drug (NSAID) in China and the first analgesic drug approved by the FDA to be manufactured in China. Additionally, it stands as the only long-acting NSAID injection available globally. The drug will be marketed under the trade names PuTanNing in China and Qamzova in the US.<\/p>\n\n\n\n<p><strong>Drug Development and Mechanism<\/strong><br>QP001 is a me-better version of Boehringer Ingelheim\u2019s Mobic (meloxicam), developed by Nanjing Delova Biotech Co., Ltd. Unlike traditional non-selective NSAIDs, QP001 is a selective cyclooxygenase-2 (COX-2) inhibitor. It reduces or blocks the synthesis of prostaglandins (PGs) in the affected area by inhibiting the upregulation of COX-2 activity at inflammation and pain sites, thereby exerting anti-inflammatory and analgesic effects.<\/p>\n\n\n\n<p><strong>Market and Licensing<\/strong><br>Sino Biopharmaceutical secured exclusive rights to QP001 in mainland China through a licensing agreement with Delova Bio in March of this year. This strategic move underscores Sino Bio\u2019s commitment to expanding its portfolio with innovative pain management solutions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 2.2 drug QP001 (meloxicam) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33691,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[908,71,15,313],"class_list":["post-33690","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-hkg-1177","tag-nmpa-fda-filing","tag-product-approvals","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharmaceutical&#039;s QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 2.2 drug QP001 (meloxicam) has received marketing approvals from China\u2019s National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA). This milestone marks QP001 as the first daily 24-hour long-acting nonsteroidal anti-inflammatory drug (NSAID) in China and the first analgesic drug approved by the FDA to be manufactured in China. Additionally, it stands as the only long-acting NSAID injection available globally. The drug will be marketed under the trade names PuTanNing in China and Qamzova in the US.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33690\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharmaceutical&#039;s QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain\" \/>\n<meta property=\"og:description\" content=\"China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 2.2 drug QP001 (meloxicam) has received marketing approvals from China\u2019s National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA). This milestone marks QP001 as the first daily 24-hour long-acting nonsteroidal anti-inflammatory drug (NSAID) in China and the first analgesic drug approved by the FDA to be manufactured in China. Additionally, it stands as the only long-acting NSAID injection available globally. The drug will be marketed under the trade names PuTanNing in China and Qamzova in the US.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33690\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-19T09:52:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-19T09:52:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1908.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33690#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33690\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharmaceutical&#8217;s QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain\",\"datePublished\":\"2025-05-19T09:52:58+00:00\",\"dateModified\":\"2025-05-19T09:52:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33690\"},\"wordCount\":213,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33690#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1908.webp\",\"keywords\":[\"HKG: 1177\",\"NMPA &amp; FDA Filing\",\"Product approvals\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33690#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33690\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33690\",\"name\":\"Sino Biopharmaceutical's QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33690#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33690#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1908.webp\",\"datePublished\":\"2025-05-19T09:52:58+00:00\",\"dateModified\":\"2025-05-19T09:52:59+00:00\",\"description\":\"China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 2.2 drug QP001 (meloxicam) has received marketing approvals from China\u2019s National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA). This milestone marks QP001 as the first daily 24-hour long-acting nonsteroidal anti-inflammatory drug (NSAID) in China and the first analgesic drug approved by the FDA to be manufactured in China. Additionally, it stands as the only long-acting NSAID injection available globally. The drug will be marketed under the trade names PuTanNing in China and Qamzova in the US.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33690#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33690\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33690#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1908.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/1908.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sino Biopharmaceutical's QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33690#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharmaceutical&#8217;s QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharmaceutical's QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 2.2 drug QP001 (meloxicam) has received marketing approvals from China\u2019s National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA). This milestone marks QP001 as the first daily 24-hour long-acting nonsteroidal anti-inflammatory drug (NSAID) in China and the first analgesic drug approved by the FDA to be manufactured in China. Additionally, it stands as the only long-acting NSAID injection available globally. The drug will be marketed under the trade names PuTanNing in China and Qamzova in the US.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33690","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharmaceutical's QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain","og_description":"China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 2.2 drug QP001 (meloxicam) has received marketing approvals from China\u2019s National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA). This milestone marks QP001 as the first daily 24-hour long-acting nonsteroidal anti-inflammatory drug (NSAID) in China and the first analgesic drug approved by the FDA to be manufactured in China. Additionally, it stands as the only long-acting NSAID injection available globally. The drug will be marketed under the trade names PuTanNing in China and Qamzova in the US.","og_url":"https:\/\/flcube.com\/?p=33690","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-19T09:52:58+00:00","article_modified_time":"2025-05-19T09:52:59+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1908.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33690#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33690"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharmaceutical&#8217;s QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain","datePublished":"2025-05-19T09:52:58+00:00","dateModified":"2025-05-19T09:52:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33690"},"wordCount":213,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33690#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1908.webp","keywords":["HKG: 1177","NMPA &amp; FDA Filing","Product approvals","Sino Biopharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33690#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33690","url":"https:\/\/flcube.com\/?p=33690","name":"Sino Biopharmaceutical's QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33690#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33690#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1908.webp","datePublished":"2025-05-19T09:52:58+00:00","dateModified":"2025-05-19T09:52:59+00:00","description":"China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 2.2 drug QP001 (meloxicam) has received marketing approvals from China\u2019s National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA). This milestone marks QP001 as the first daily 24-hour long-acting nonsteroidal anti-inflammatory drug (NSAID) in China and the first analgesic drug approved by the FDA to be manufactured in China. Additionally, it stands as the only long-acting NSAID injection available globally. The drug will be marketed under the trade names PuTanNing in China and Qamzova in the US.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33690#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33690"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33690#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1908.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1908.webp","width":1080,"height":608,"caption":"Sino Biopharmaceutical's QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33690#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharmaceutical&#8217;s QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/1908.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33690"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33690\/revisions"}],"predecessor-version":[{"id":33692,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33690\/revisions\/33692"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33691"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33690"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33690"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}